Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**calmangafodipir + acetylcysteine** is a combination therapy under investigation for treating paracetamol (acetaminophen) overdose. Calmangafodipir acts as a superoxide dismutase mimetic (SOD mimetic) designed to protect against oxidative stress and hepatotoxicity. Acetylcysteine is the established antidote for acetaminophen overdose, functioning primarily by replenishing hepatic glutathione and promoting the detoxification of reactive metabolites. Combining calmangafodipir with acetylcysteine may offer enhanced protection of liver cells, particularly in patients at higher risk for liver injury or presenting later after overdose, by mitigating oxidative damage and reducing biomarkers of hepatotoxicity[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calmangafodipir + acetylcysteine.